Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - ImmunoCellular Therapeutics, Ltd. | imuc-63017xexhibit321.htm |
| EX-31.2 - EXHIBIT 31.2 - ImmunoCellular Therapeutics, Ltd. | imuc-63017xexhibit312.htm |
| EX-31.1 - EXHIBIT 31.1 - ImmunoCellular Therapeutics, Ltd. | imuc-63017xexhibit311.htm |
| EX-4.3 - EXHIBIT 4.3 - ImmunoCellular Therapeutics, Ltd. | exhibit43.htm |
| EX-4.2 - EXHIBIT 4.2 - ImmunoCellular Therapeutics, Ltd. | exhibit42.htm |
| EX-4.1 - EXHIBIT 4.1 - ImmunoCellular Therapeutics, Ltd. | exhibit41.htm |
| 10-Q - 10-Q - ImmunoCellular Therapeutics, Ltd. | imuc-63017x10q.htm |
Exhibit 32.2
CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER
Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), the undersigned officer of ImmunoCellular Therapeutics, Ltd. (the “Company”) hereby certifies that, to the best of his knowledge:
1. | The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2017 (“Periodic Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and |
2. | The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: August 14, 2017 | By: | /s/ David Fractor | |
Name: | David Fractor | ||
Title: | Chief Financial Officer | ||